跳轉至內容
Merck
  • Treatment of a tongue lymphangioma with sirolimus after failure of surgical resection and propranolol.

Treatment of a tongue lymphangioma with sirolimus after failure of surgical resection and propranolol.

Pediatric blood & cancer (2013-11-23)
Canan Akyüz, Erman Ataş, Ali Varan
摘要

Lymphangiomas of the tongue are rare, and their treatment is problematic. A 10 year-old patient with tongue lymphangioma who was previously treated with surgery and propranolol with no response was treated with sirolimus in our department. We used sirolimus with a dose of 1.6 mg/m(2)/day. After 3 months of treatment, the mass had decreased by more than 60%. We continued the treatment for 1 year with a maximum response of 70% decrease in mass. Disease remained stable 6 months after stopping therapy, the latest time of follow-up. Sirolimus appears to be effective in lymphangioma but requires further study.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
(±)-普萘洛尔 盐酸盐, ≥99% (TLC), powder
Supelco
盐酸普萘洛尔, Pharmaceutical Secondary Standard; Certified Reference Material
USP
(±)-普萘洛尔 盐酸盐, United States Pharmacopeia (USP) Reference Standard
Supelco
普萘洛尔 盐酸盐 溶液, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
Supelco
(±)-普萘洛尔 盐酸盐, analytical standard
普萘洛尔 盐酸盐, European Pharmacopoeia (EP) Reference Standard